[HTML] frontiersin.org

[HTML][HTML] Gastrointestinal adverse events associated with semaglutide: a pharmacovigilance study based on FDA adverse event reporting system

Y Shu, X He, P Wu, Y Liu, Y Ding, Q Zhang - Frontiers in public health, 2022 - frontiersin.org
Background Semaglutide was approved for treatment of type 2 diabetes mellitus (T2DM)
and chronic weight management in obesity or overweight adults. However, real-world data …
被引用次数：39 相关文章

Gastrointestinal adverse events associated with semaglutide: A pharmacovigilance study based on FDA adverse event reporting system

Y Shu, X He, P Wu, Y Liu, Y Ding… - Frontiers in public …, 2022 - pubmed.ncbi.nlm.nih.gov
Background Semaglutide was approved for treatment of type 2 diabetes mellitus (T2DM)
and chronic weight management in obesity or overweight adults. However, real-world data …

Gastrointestinal adverse events associated with semaglutide: A pharmacovigilance study based on FDA adverse event reporting system

Y Shu, X He, P Wu, Y Liu, Y Ding… - Frontiers in Public …, 2022 - europepmc.org
Background Semaglutide was approved for treatment of type 2 diabetes mellitus (T2DM)
and chronic weight management in obesity or overweight adults. However, real-world data …
[HTML] frontiersin.org

[HTML][HTML] Gastrointestinal adverse events associated with semaglutide: A pharmacovigilance study based on FDA adverse event reporting system

Y Shu, X He, Y Ding, Q Zhang - Frontiers in Public Health, 2022 - frontiersin.org
Background Semaglutide was approved for treatment of type 2 diabetes mellitus (T2DM)
and chronic weight management in obesity or overweight adults. However, real-world data …
[HTML] nih.gov

[HTML][HTML] Gastrointestinal adverse events associated with semaglutide: A pharmacovigilance study based on FDA adverse event reporting system

Y Shu, X He, P Wu, Y Liu, Y Ding… - Frontiers in Public …, 2022 - ncbi.nlm.nih.gov
Background Semaglutide was approved for treatment of type 2 diabetes mellitus (T2DM)
and chronic weight management in obesity or overweight adults. However, real-world data …

Gastrointestinal adverse events associated with semaglutide: A pharmacovigilance study based on FDA adverse event reporting system.

Y Shu, X He, P Wu, Y Liu, Y Ding… - Frontiers in Public …, 2022 - europepmc.org
Background Semaglutide was approved for treatment of type 2 diabetes mellitus (T2DM)
and chronic weight management in obesity or overweight adults. However, real-world data …